These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34740705)

  • 1. EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study.
    Ratziu V; Rinella ME; Neuschwander-Tetri BA; Lawitz E; Denham D; Kayali Z; Sheikh A; Kowdley KV; Desta T; Elkhashab M; DeGrauw J; Goodwin B; Ahmad A; Adda N
    J Hepatol; 2022 Mar; 76(3):506-517. PubMed ID: 34740705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
    Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ
    J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH.
    Ratziu V; Harrison SA; Loustaud-Ratti V; Bureau C; Lawitz E; Abdelmalek M; Alkhouri N; Francque S; Girma H; Darteil R; Couchoux H; Wolf M; Sanyal A; Vonderscher J; Scalfaro P
    J Hepatol; 2023 Mar; 78(3):479-492. PubMed ID: 36334688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
    Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
    Harrison SA; Ruane PJ; Freilich B; Neff G; Patil R; Behling C; Hu C; Shringarpure R; de Temple B; Fong E; Tillman EJ; Rolph T; Cheng A; Yale K
    JHEP Rep; 2023 Jan; 5(1):100563. PubMed ID: 36644237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
    Newsome PN; Palmer M; Freilich B; Sheikh MY; Sheikh A; Sarles H; Herring R; Mantry P; Kayali Z; Hassanein T; Lee HM; Aithal GP;
    J Hepatol; 2020 Aug; 73(2):231-240. PubMed ID: 32234329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
    Younossi ZM; Ratziu V; Loomba R; Rinella M; Anstee QM; Goodman Z; Bedossa P; Geier A; Beckebaum S; Newsome PN; Sheridan D; Sheikh MY; Trotter J; Knapple W; Lawitz E; Abdelmalek MF; Kowdley KV; Montano-Loza AJ; Boursier J; Mathurin P; Bugianesi E; Mazzella G; Olveira A; Cortez-Pinto H; Graupera I; Orr D; Gluud LL; Dufour JF; Shapiro D; Campagna J; Zaru L; MacConell L; Shringarpure R; Harrison S; Sanyal AJ;
    Lancet; 2019 Dec; 394(10215):2184-2196. PubMed ID: 31813633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
    Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
    J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study.
    Harrison SA; Alkhouri N; Davison BA; Sanyal A; Edwards C; Colca JR; Lee BH; Loomba R; Cusi K; Kolterman O; Cotter G; Dittrich HC
    J Hepatol; 2020 Apr; 72(4):613-626. PubMed ID: 31697972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
    Patel K; Harrison SA; Elkhashab M; Trotter JF; Herring R; Rojter SE; Kayali Z; Wong VW; Greenbloom S; Jayakumar S; Shiffman ML; Freilich B; Lawitz EJ; Gane EJ; Harting E; Xu J; Billin AN; Chung C; Djedjos CS; Subramanian GM; Myers RP; Middleton MS; Rinella M; Noureddin M
    Hepatology; 2020 Jul; 72(1):58-71. PubMed ID: 32115759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
    Harrison SA; Neff G; Guy CD; Bashir MR; Paredes AH; Frias JP; Younes Z; Trotter JF; Gunn NT; Moussa SE; Kohli A; Nelson K; Gottwald M; Chang WCG; Yan AZ; DePaoli AM; Ling L; Lieu HD
    Gastroenterology; 2021 Jan; 160(1):219-231.e1. PubMed ID: 32781086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study.
    Loomba R; Lawitz EJ; Frias JP; Ortiz-Lasanta G; Johansson L; Franey BB; Morrow L; Rosenstock M; Hartsfield CL; Chen CY; Tseng L; Charlton RW; Mansbach H; Margalit M
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):120-132. PubMed ID: 36521501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
    Harrison SA; Wong VW; Okanoue T; Bzowej N; Vuppalanchi R; Younes Z; Kohli A; Sarin S; Caldwell SH; Alkhouri N; Shiffman ML; Camargo M; Li G; Kersey K; Jia C; Zhu Y; Djedjos CS; Subramanian GM; Myers RP; Gunn N; Sheikh A; Anstee QM; Romero-Gomez M; Trauner M; Goodman Z; Lawitz EJ; Younossi Z; ;
    J Hepatol; 2020 Jul; 73(1):26-39. PubMed ID: 32147362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Harrison SA; Rinella ME; Abdelmalek MF; Trotter JF; Paredes AH; Arnold HL; Kugelmas M; Bashir MR; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Loomba R
    Lancet; 2018 Mar; 391(10126):1174-1185. PubMed ID: 29519502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
    Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
    Neuschwander-Tetri BA; Loomba R; Sanyal AJ; Lavine JE; Van Natta ML; Abdelmalek MF; Chalasani N; Dasarathy S; Diehl AM; Hameed B; Kowdley KV; McCullough A; Terrault N; Clark JM; Tonascia J; Brunt EM; Kleiner DE; Doo E;
    Lancet; 2015 Mar; 385(9972):956-65. PubMed ID: 25468160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
    Harrison SA; Frias JP; Neff G; Abrams GA; Lucas KJ; Sanchez W; Gogia S; Sheikh MY; Behling C; Bedossa P; Shao L; Chan D; Fong E; de Temple B; Shringarpure R; Tillman EJ; Rolph T; Cheng A; Yale K;
    Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1080-1093. PubMed ID: 37802088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
    Alkhouri N; Herring R; Kabler H; Kayali Z; Hassanein T; Kohli A; Huss RS; Zhu Y; Billin AN; Damgaard LH; Buchholtz K; Kjær MS; Balendran C; Myers RP; Loomba R; Noureddin M
    J Hepatol; 2022 Sep; 77(3):607-618. PubMed ID: 35439567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
    Harrison SA; Goodman Z; Jabbar A; Vemulapalli R; Younes ZH; Freilich B; Sheikh MY; Schattenberg JM; Kayali Z; Zivony A; Sheikh A; Garcia-Samaniego J; Satapathy SK; Therapondos G; Mena E; Schuppan D; Robinson J; Chan JL; Hagerty DT; Sanyal AJ
    J Hepatol; 2020 May; 72(5):816-827. PubMed ID: 31887369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.